• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    National Research Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    5/12/25 9:01:47 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    nrc20250509_8k.htm
    false 0000070487 0000070487 2025-05-07 2025-05-07
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported):
    May 7, 2025
     

     
    National Research Corporation
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-35929
    47-0634000
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
     
    1245 Q Street, Lincoln, Nebraska
    68508
    (Address of principal executive offices)
    (Zip Code)
     
    (402) 475-2525
    (Registrant’s telephone number, including area code)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    $0.001 Par Value Common Stock NRC The NASDAQ Stock Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On May 7, 2025, the shareholders of National Research Corporation, a Delaware corporation (the “Company”), approved the National Research Corporation 2025 Omnibus Incentive Plan (the “2025 Omnibus Incentive Plan”). The 2025 Omnibus Incentive Plan became effective on May 7, 2025, and replaces the National Research Corporation 2006 Equity Incentive Plan and the National Research Corporation 2004 Non-Employee Director Stock Plan, as amended. 
     
    The terms of the 2025 Omnibus Incentive Plan are described in the Company’s proxy statement for the 2025 Annual Meeting of Shareholders (the “Annual Meeting”) filed with the Securities and Exchange Commission on April 10, 2025 (the “Proxy Statement”) in the section thereof titled “Proposal 4 – Approval of the National Research Corporation 2025 Omnibus Incentive Plan.” The text of the 2025 Omnibus Incentive Plan is set forth as Appendix A to the Proxy Statement.
     
    Item 5.07
    Submission of Matters to a Vote of Security Holders.
     
    The Annual Meeting was held on May 7, 2025. Four proposals were voted on at the Annual Meeting. The proposals are described in detail in the Proxy Statement. The final results for the votes regarding each proposal are set forth below.
     
    1.
    Donald M. Berwick and Stephen H. Lockhart were elected to serve as directors for three-year terms to expire at the Company’s 2028 annual meeting of shareholders:
     
    Name
     
    For
     
    Against
     
    Abstain
     
    Broker
    Non-Votes
    Donald M. Berwick
     
    20,930,792
     
    103,066
     
    22,243
     
    829,100
    Stephen H. Lockhart
     
    20,950,429
     
    80,649
     
    25,023
     
    829,100
     
    2.
    The appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2025 was ratified:
     
    For
     
    Against
     
    Abstain
     
    Broker
    Non-Votes
    21,710,551
     
    172,003
     
    2,647
     
    —
     
    3.
    The compensation of the Company’s named executive officers as described in the Proxy Statement was approved on an advisory and non-binding basis:
     
    For
     
    Against
     
    Abstain
     
    Broker
    Non-Votes
    20,655,974
     
    217,494
     
    182,633
     
    829,100
     
    4.
    The 2025 Omnibus Incentive Plan was approved:
     
    For
     
    Against
     
    Abstain
     
    Broker
    Non-Votes
    16,852,672
     
    4,017,318
     
    186,111
     
    829,100
     
     

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    NATIONAL RESEARCH CORPORATION
     
    (Registrant)
     
         
    Date: May 12, 2025
    By:
    /s/ Michael D. Hays
       
    Michael D. Hays
       
    Chief Executive Officer
     
     
     
    Get the next $NRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • A New Era of Trust: NRC Health's 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience

      NRC Health unveils its 2025 Experience Perspective Report, highlighting new research and trends shaping the future of healthcare, with a focus on trust, generational shifts, and evolving consumer demands. NRC Health, a recognized leader in healthcare experience management solutions to transform interactions for patients, consumers, and employees alike, released its 2025 Experience Perspective today during a live national webcast. Known for delivering premier market research and data-driven insights, NRC Health's report features key findings and strategic recommendations based on extensive research involving millions of consumers, patients, and other healthcare leaders nationwide. Guided b

      4/10/25 2:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Financials

    Live finance-specific insights

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Announces Fourth Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $58.5 million. Total recurring contract value (TRCV) was approximately $133.2 million at December 31, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $10.1 millio

      1/27/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    SEC Filings

    See more
    • National Research Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/12/25 9:01:47 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by National Research Corporation

      10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/9/25 10:02:32 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      4/28/25 5:12:02 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Bhandari Parul

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/9/25 5:11:12 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Wheeler Penny Ann

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/9/25 5:09:46 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Research Corporation

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      11/13/24 4:05:19 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by National Research Corporation (Amendment)

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/8/24 4:05:05 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by National Research Corporation (Amendment)

      SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/5/24 4:31:31 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    See more
    • National Research Corporation Appoints Trent Green as Chief Executive Officer

      National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

      3/4/25 4:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer

      Baron will align and advance NRC Health's experience solutions platform to solve health care industry challenges and continue effectively innovating and supporting experience improvement for health systems across the nation. NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho

      4/2/24 11:55:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

      NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions. The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners. Four newly created executive leadership roles will guide NRC Health's strategy and success, including: Helen Hrdy, Chief Customer Officer Jason Hahn, Chief Revenue Officer Christophe Louvion, Chief Product Technology Officer Andy Monnich, Chief Corporate Development Officer "Strong leadership is key in driving innovation and meeting the ever-evolv

      2/1/24 10:00:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care